Our team of R&D leaders from human biotech and animal health is building the premier biotechnology platform for protein-based therapeutics in animal health.
Location: United States, Massachusetts, Boston
Total raised: $101M
Investors 4
| Date | Name | Website |
| - | Anterra Ca... | anterracap... |
| 10.06.2023 | F-Prime Ca... | fprimecapi... |
| 28.05.2022 | Eight Road... | eightroads... |
| 09.08.2022 | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.05.2022 | Series B | $60.5M | GlobeLab |
| 01.10.2020 | Series A | $25.5M | - |
| 24.02.2020 | Series A | $15M | - |
Mentions in press and media 17
| Date | Title | Description |
| 27.08.2025 | Harbour BioMed Reports 2025 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ... |
| 03.02.2025 | Nona Biosciences Announces Strategic Collaboration with Invetx for Next-Generation Animal Health Biotherapeutics Discovery | CAMBRIDGE, Mass., Feb. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), announced today that it has entered into a strategic collaboration with ... |
| 01.04.2024 | Old Dogs Can Inspire New Business Models | 13 Shares Email Facebook Twitter LinkedIn People with puppies are tired. People with senior dogs are broke. That, in oversimplified terms, is a pretty consistent anecdotal finding among pet owners. As furry friends age, their people face th... |
| 10.05.2022 | Our investment in Invetx | Invetx is positioned to bring portfolio of novel antibody product candidates through development to market approval. The investment was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation... |
| 10.05.2022 | Invetx announces oversubscribed Series B financing of $60.5 million to advance portfolio of best-in-class veterinary biotherapeutics | From Invetx.com |
| 10.05.2022 | Invetx Raises $60.5M in Series B Funding | Invetx, a Boston, MA-based pioneer in protein-based therapeutics for animal health, raised $60.5m in Series B financing. The round was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation ... |
| 10.05.2022 | Invetx raises $60.5 million to make long-lasting antibody therapies for cats and dogs | - |
| 06.01.2021 | Former Head of Boehringer Ingelheim Animal Health, Dr. Joachim Hasenmaier, Joins Invetx Board of Directors | BOSTON, Mass. – January 6, 2021 – Invetx, a pioneer in protein-based therapeutics for animal health, announced today that Dr. Joachim Hasenmaier has joined the company’s board of directors. |
| 01.10.2020 | Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team | New Investors Include Casdin Capital and Tekla Capital |
| 30.09.2020 | Invetx Secures $25.5M in Series A | BOSTON, MA, Invetx announced today that it has raised an additional $10.25 million in its Series A financing, bringing the total amount to $25.5 million. >> Click here for more funding data on Invetx >> To export Invetx fund... |
Show more